Innospec (IOSP) & Its Rivals Head to Head Survey

Innospec (NASDAQ: IOSP) is one of 52 publicly-traded companies in the “Specialty Chemicals” industry, but how does it compare to its rivals? We will compare Innospec to similar businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, risk and dividends.

Dividends

Innospec pays an annual dividend of $0.76 per share and has a dividend yield of 1.2%. Innospec pays out 24.3% of its earnings in the form of a dividend. As a group, “Specialty Chemicals” companies pay a dividend yield of 1.4% and pay out 27.2% of their earnings in the form of a dividend.

Analyst Recommendations

This is a summary of current ratings and price targets for Innospec and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innospec 0 0 1 0 3.00
Innospec Competitors 162 1016 1270 24 2.47

Innospec presently has a consensus target price of $65.00, indicating a potential upside of 3.17%. As a group, “Specialty Chemicals” companies have a potential downside of 1.82%. Given Innospec’s stronger consensus rating and higher probable upside, research analysts plainly believe Innospec is more favorable than its rivals.

Profitability

This table compares Innospec and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innospec 7.22% 14.77% 8.39%
Innospec Competitors -2.31% 9.38% 4.07%

Earnings and Valuation

This table compares Innospec and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Innospec $1.06 billion $150.30 million 20.13
Innospec Competitors $1.96 billion $301.94 million 16.83

Innospec’s rivals have higher revenue and earnings than Innospec. Innospec is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Innospec has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Innospec’s rivals have a beta of 1.59, meaning that their average stock price is 59% more volatile than the S&P 500.

Institutional & Insider Ownership

90.7% of Innospec shares are held by institutional investors. Comparatively, 69.9% of shares of all “Specialty Chemicals” companies are held by institutional investors. 2.0% of Innospec shares are held by insiders. Comparatively, 7.1% of shares of all “Specialty Chemicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Innospec beats its rivals on 8 of the 15 factors compared.

About Innospec

Innospec Inc. is a specialty chemicals company engaged in developing, manufacturing, blending, marketing and supplying of specialty chemicals for use as fuel additives and ingredients for personal care, home care, agrochemical, mining and other applications and oilfield chemicals. The Company operates through four business segments: Fuel Specialties, Performance Chemicals, Oilfield Services and Octane Additives. Its Fuel Specialties develops, manufactures, blends, markets and supplies various specialty chemical products that are used as additives for a range of fuels. Its Performance Chemicals provides technology-based solutions. Its Oilfield Services business supplies drilling, completion and production chemicals. Its Octane Additives business manufactures a fuel additive for use in automotive gasoline and provides services in respect of environmental remediation. Its customers include oil and gas exploration and production companies, fuel users, and oil refiners among others.

Receive News & Ratings for Innospec Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply